01—Abstract
Summary
Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
BeOne Medicines Ltd. reported a strong second quarter for 2026, with total revenues increasing by 29.6% year-over-year to $1.71 billiona.
This growth was primarily driven by a 29.0% increase in product revenue, largely attributed to robust global sales of BRUKINSA®, which saw a 31.4% year-over-year increase. The company also experienced significant growth in other revenue streams, up 91.1%, indicating positive momentum across its portfolio. Despite increased revenue, net income saw a substantial increase of 151.3% to $237 millionb, reflecting improved operating leverage and effective cost management, as demonstrated by the increase in gross margin to 89.6%.
Research and development expenses increased by 16.6%c, supporting pipeline advancement, while selling, general, and administrative expenses grew by 10.3%, primarily due to global commercial expansion. The company generated strong operating cash flow, a key indicator of financial health and sustainability.
02—Key points
Key Highlights
- Total revenues reached $1.71 billion, a 29.6% increase year-over-year.
- Product revenue increased by 29.0% to $1.68 billion.
- BRUKINSA® sales grew by 31.4% year-over-year to $1.25 billion for the quarter.
- Net income surged by 151.3% to $237.0 million.
- Gross margin improved to 89.6% from 87.4% in the prior year period.
- Research and development expenses increased 16.6% to $612.3 million, supporting pipeline advancement.
- Cash, cash equivalents, and restricted cash stood at $5.28 billion as of June 30, 2026.
03—Questions
Frequently Asked Questions
What was BeOne Medicines Ltd.'s revenue for the second quarter of 2026?
BeOne Medicines Ltd.'s total revenues for the three months ended June 30, 2026, were $1.71 billion, representing a 29.6% increase compared to $1.32 billion in the same period of 2025.
What drove the significant increase in net income?
The substantial increase in net income to $237.0 million was primarily driven by strong revenue growth, particularly from BRUKINSA®, and improved operating leverage, which led to a higher gross margin. Effective management of operating expenses also contributed to the net income improvement.
How did BRUKINSA® perform in the second quarter of 2026?
BRUKINSA® sales showed strong performance, reaching $1.25 billion for the three months ended June 30, 2026, a 31.4% increase compared to $950 million in the prior-year period. This growth was attributed to robust demand in the U.S. and Europe, and continued market share gains.
What is the company's cash position?
As of June 30, 2026, BeOne Medicines Ltd. had $5.28 billion in cash, cash equivalents, and restricted cash, indicating a strong liquidity position.
04—Continue